Exact Sciences to Participate in December Investor Conferences




Exact Sciences to Participate in December Investor Conferences

MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Citi Global Healthcare Conference, Miami
  
  Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET

• Evercore HealthCONx Conference, Miami
  
  Fireside chat on Wednesday, December 4, 2024 at 7:30 a.m. ET

The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Erik Holznecht

Exact Sciences Corp.

investorrelations@exactsciences.com
608-800-6605

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323




Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

TOKUSHIMA, Japan–(BUSINESS WIRE)–We are excited to share our latest development status.

Similar to its position in the United States, we are pleased to announce that Afatinib, which is being treated with DFP-14323 in our ongoing Phase III clinical trial, has been approved by the Japanese Lung Cancer Society in its “Lung Cancer Treatment Guidelines 2024” (issued on October 20, 2024) as a first-line treatment for EGFR mutation-positive (uncommon mutation) non-small cell lung cancer (NSCLC), with a stronger recommendation than Osimertinib.

The development of DFP-14323 is being conducted in patients (stage III/IV) with epidermal growth factor receptor (EGFR) mutation-positive uncommon mutation NSCLC in a Phase III clinical trial (superiority study) comparing DFP-14323 in combination with Afatinib (20 mg/day) and Afatinib (40 mg/day) alone. The strongly recommended treatment with afatinib as first-line therapy must accelerate the enrollment of NSCLC patients through this trial.

The study is being conducted at 30 core hospitals throughout Japan involved in the treatment of NSCLC, and clinical efficacy will be finally determined by progression-free survival (PFS). DFP-14323 is a small molecule substance (oral absorption rate of approximately 100%) that inhibits the CD13/APN receptor, which is frequently found on cells in NSCLC including cancer stem cells. We plan to promote it for development collaboration with a global pharmaceutical company.

Please take notice of our own innovative approach for miserable cancer patients and contact us.

Contacts

Inquires

Yasundo Yamasaki, Ph.D.

Director, Business Development

Delta-Fly Pharma Inc.

Head office: Tokushima 771-0117, Japan

Phone: +81-3-6231-1278

E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/

Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study




Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study

• To date, more than 50% of the patients in the study have been enrolled in seven European countries.
• The study is testing AC102 as a novel, more effective treatment for sudden hearing loss with fewer side effects.

BERLIN–(BUSINESS WIRE)–Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for new therapies.

This enrollment milestone is an important step in the development of AC102 and in addressing the unmet medical need for sudden hearing loss. The safety and tolerability of AC102 has already been successfully tested in healthy volunteers. “Recruitment for the trial is challenging because the compound can only be effective in the first few days after the onset of the sudden hearing loss and we can therefore only enroll patients in the study during this short window. I am therefore very pleased with this recruitment success, which underscores the high level of interest in new, more effective treatment options for patients with sudden hearing loss,” explains the coordinating investigator, Prof. Dr. Stefan Plontke of Martin-Luther-University Halle-Wittenberg.

AC102 is considered a promising alternative to corticoid therapy for sudden hearing loss, as it was able to restore hearing almost completely in an acoustic trauma model after a single application in a preclinical study¹ This work also revealed the mechanism of action of AC102. Unlike the non-specific, anti-inflammatory effects of corticoids, AC102 specifically targets the sensory cells and synaptic connections in the inner ear that are responsible for hearing loss. “Our goal is to achieve a paradigm shift in the treatment of sudden hearing loss with the specific effect of AC102 and to contribute to better help sudden hearing loss patients in the future,” said Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma.

The Phase 2 trial is expected to continue enrolling patients until end of 2025.

¹Rommelspacher H, et al., PNAS. 2024 Apr 9;121(15)

Contacts

AudioCure Pharma GmbH

Frauke Luers

Phone: +49 30 2218 397-0

E-Mail: pr@ac-clinical.com
Web: www.audiocure.com

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis




Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis

WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality

Study to be stopped early and participants will be offered the opportunity to receive WINREVAIR

Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH

RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours). In the study, WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive WINREVAIR through the SOTERIA open-label extension study. In preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.

“PAH is a serious, progressive disease with a high incidence of morbidity and mortality,” said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “Based on the primary endpoint demonstrating overwhelming efficacy, all ZENITH study participants will be offered the opportunity to receive WINREVAIR. These findings are impressive, set a high evidentiary bar for studies of future candidates developed for the treatment of PAH and support the potential of WINREVAIR to be practice-changing in the management of PAH.”

“The ZENITH trial was designed to evaluate whether the addition of WINREVAIR, an activin signaling inhibitor, could reduce the risk of death, lung transplantation, or PAH hospitalizations for patients living with advanced PAH,” said Dr. Vallerie McLaughlin**, Kim A Eagle MD Endowed Professor of Cardiovascular Medicine and Director, Pulmonary Hypertension Program, University of Michigan in Ann Arbor. “This is the first study in PAH in which the interim analysis led to an early conclusion of the study due to overwhelming efficacy. WINREVAIR has brought significant optimism to the field, and we thank the investigators and patients for being part of this important study.”

WINREVAIR is currently approved in the U.S. and 36 countries based on the results from the Phase 3 STELLAR trial. Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.

Results from ZENITH will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

*World Health Organization

** Dr. McLaughlin is an investigator in the ZENITH trial and a paid consultant to Merck.

About ZENITH

The ZENITH study (NCT04896008) is a global, double-blind, placebo-controlled clinical trial to evaluate WINREVAIR when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours, in participants with WHO FC III or IV PAH at high risk of mortality. ZENITH study inclusion criteria required Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 risk score of ≥9.

The study enrolled 172 participants, who were randomized in a 1:1 ratio to either WINREVAIR plus background PAH therapy or placebo plus background PAH therapy. The primary composite outcome measure is time to first confirmed morbidity or mortality event. Events are defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥ 24 hours. Secondary outcome measures include overall survival, transplant-free survival and several additional measures. Participants who have completed the ZENITH trial have the opportunity to receive sotatercept as part of the open-label, long-term extension study, SOTERIA (NCT04796337), consistent with that study’s eligibility criteria.

About WINREVAIR^™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg

WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics.

WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.

Selected Safety Information for WINREVAIR in the U.S.

WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.

WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm3. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required.

In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding.

WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.

Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.

The most common adverse reactions occurring in the phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5%), epistaxis (22.1% vs 1.9%), rash (20.2% vs 8.1%), telangiectasia (16.6% vs 4.4%), diarrhea (15.3% vs 10.0%), dizziness (14.7% vs 6.2%), and erythema (13.5% vs 3.1%).

Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.

About PAH

Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the U.S. are living with PAH. The disease progresses rapidly for many patients. PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Please see Prescribing Information for WINREVAIR (sotatercept-csrk) at http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf, Patient Information for WINREVAIR at http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ppi.pdf, and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) at https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ifu_1-vial_2-vial_kits.pdf.

Contacts

Media Contacts:

Julie Cunningham

(617) 519-6264

Ayn Wisler

(917) 691-6218

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

Steven Graziano

(732) 594-1583

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference




Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

HENDERSON, Nev.–(BUSINESS WIRE)–$ZURA #TeamZura—Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY.

A live webcast and a replay of the presentation will be available on the “News & Events” page within the Investors section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the events.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

Contacts

Megan K. Weinshank

Head of Corporate Affairs

ir@zurabio.com

Metrion Biosciences appoints Lee Patterson as CEO




Metrion Biosciences appoints Lee Patterson as CEO

Significant CRO C-suite experience expected to drive growth and commercial expansion into global markets

CAMBRIDGE, England–(BUSINESS WIRE)–Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2^nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.

A renowned leader in the sector, Lee Patterson specializes in steering preclinical CROs to implement robust and effective plans for long-term commercial growth. Previously CEO at Charnwood Discovery, a provider of integrated drug discovery services with a global biotech and pharma client base, he led the company through its successful acquisition by Concept Life Sciences in October 2024. Prior to this, Lee served as Chief Operating Officer at Quanticate, a global biometrics CRO, and Chief Operating Officer at Concept Life Sciences. He also held several executive roles at Covance/Labcorp, the most recent being Executive Director, Global Operations and Early Development Management Office.

Lee will join recently appointed CCO Dr Chris Mathes as the latest addition to Metrion’s senior leadership team¹. Working closely alongside Chris and the broader management team, Lee’s C-suite level expertise and experience will support Metrion to bolster its global commercial presence and scientific capabilities.

Outgoing CEO Dr Andrew Southan has led Metrion successfully since 2019, more than doubling revenues over that time and overseeing the Company’s growth in staffing, laboratory facilities and international client base. He also led the Company’s successful £3.7M equity financing round in December 2023.

“On behalf of the Board and management team, I would like to thank Andy Southan for his dedicated leadership over the last five years, in particular establishing Metrion’s reputation as a high quality, specialist CRO and a leading centre of expertise in ion channel biology,” said Keith McCullagh, Chairman, Metrion Biosciences. “At the same time, I am delighted to welcome Lee Patterson to the Company. His experience of leading commercial CROs and his expertise in enhancing operational efficiencies are both outstanding and we look forward to working with him to continue Metrion’s growth as a specialist CRO serving global markets.”

Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has built an impressive reputation in ion channel drug discovery, with proven commitment to outstanding customer service and world class science. I am excited to join this talented team and look forward to working with them to enhance and expand our specialised services to meet the needs of our clients worldwide.”

1. Press Release (23rd July, 2024): Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

Contacts

Media Contact
Katie Odgaard

Zyme Communications

E-mail: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference




Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

SKILLMAN, N.J.–(BUSINESS WIRE)–Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company’s participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. Thibaut Mongon, Chief Executive Officer and Paul Ruh, Chief Financial Officer will participate in a fireside chat on Wednesday, December 4, 2024, at 11:45 a.m. Eastern Time. A live webcast of the fireside chat will be available on investors.kenvue.com and a replay will be available on the website following the event.

About Kenvue

Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno^®, BAND-AID^® Brand, Johnson’s^®, Listerine^®, Neutrogena^® and Tylenol^®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

Contacts

Investor Relations:
Sofya Tsinis

Kenvue_IR@Kenvue.com

Media Relations:
Melissa Witt

media@kenvue.com

AgelessRx Enters Sleep Health Category, Underscoring Critical Role Sleep Plays in Healthspan and Lifespan




AgelessRx Enters Sleep Health Category, Underscoring Critical Role Sleep Plays in Healthspan and Lifespan

Leading longevity telehealth platform expands portfolio, adding personalized prescription and natural sleep treatment options to support health and well-being

ANN ARBOR, Mich.–(BUSINESS WIRE)–AgelessRx, a pioneer in longevity and telehealth solutions, today announced its entry into the sleep health category, building on its commitment to redefine aging and improve quality of life. With a strong emphasis on research-backed solutions, AgelessRx’s sleep program provides personalized sleep treatment plans, and two new products–prescription Trazodone and natural, over-the-counter (OTC) Tran-Q Sleep Supplement–alongside easy-to-adopt lifestyle recommendations. Guided by the latest scientific insights into sleep health, AgelessRx sleep regimens are effective, tailored to customers’ unique needs, and integrated into holistic, personalized treatment plans focused on extending lifespan and enhancing healthspan.

Quality sleep is the cornerstone of cognitive and physical health, reducing the risk of chronic conditions like heart disease, diabetes, and obesity, which are linked to shorter lifespans. 1 in 3 Americans report sub-optimal sleep with the demands and distractions of modern lifestyles frequently deprioritizing rest and undermining sleep. AgelessRx’s tailored sleep solutions address this growing health crisis and are part of its ongoing mission to support the most important aspects of proactive healthcare.

“Advances in research and understanding of sleep architecture underscores the importance of sleep as a major determinant of health and longevity—it’s our health insurance,” said Dr. Sajad Zalzala, co-founder and chief medical officer of AgelessRx. “The negative impacts of poor sleep outweigh any positive contributions proper diet and adequate exercise can offer. Our goal is to ensure this critical function is a core part of everyone’s longevity routine.”

Trazodone and Tran-Q Sleep

AgelessRx’s new offerings are oral, non-habit forming interventions that support all four pillars of sleep: quantity, quality, regularity, and timing. Trazodone is a prescription medication with well-researched use as a safe, effective sleep aid and Tran-Q Sleep is a natural, melatonin-free OTC supplement designed for relaxation and sleep support.

AgelessRx’s clinical team thoroughly reviews every patient’s medical history, unique needs, and health goals to determine the appropriate treatment for each individual. Together, these options serve a broad range of needs for people seeking improved sleep quality and sleep architecture—the process by which we cycle through different sleep stages.

• Trazodone (Rx): Studies show that Trazodone is effective at improving sleep onset and reducing nighttime awakenings and that Trazodone lowers the volume of three key neurochemical systems associated with waking: serotonin, histamine, and noradrenaline. Trazodone is recognized as a well-tolerated long-term intervention that has few side effects, boosting deep sleep without impacting rapid eye movement (REM) sleep, and minimizing next-day drowsiness.
• Tran-Q Sleep (OTC): Formulated with all-natural herbal ingredients, including passionflower and lavender, Tran-Q Sleep enhances the calming neurotransmitter (GABA) signaling and relaxes muscles while counter-balancing an overstimulated nervous system to gently prepare the mind and body for restful sleep. As a non-prescription option, Tran-Q Sleep caters to those seeking a natural solution for sleep improvement.

For additional information about AgelessRx and its sleep products and services, please visit agelessrx.com.

About AgelessRx

AgelessRx is at the forefront of the longevity revolution, offering clinically validated cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, and Facebook.

Contacts

Media contact:
JackTaylor PR

agelessrx@jacktaylorpr.com

Vitality Acquires WellSpark to Enhance Integrated Coaching Capabilities




Vitality Acquires WellSpark to Enhance Integrated Coaching Capabilities

Strategic acquisition aims to bolster Vitality’s comprehensive health and wellness offerings by integrating WellSpark’s advanced coaching solutions.

CHICAGO–(BUSINESS WIRE)–Vitality, the global behavior change platform committed to making people healthier, has today announced the strategic acquisition of WellSpark, a leading coaching provider, from EmblemHealth.

Through the acquisition, Vitality will integrate WellSpark’s coaching solutions, offering Vitality’s employer and health plan clients access to a range of new services and additional tools to support their health and wellbeing. WellSpark’s health coaches have a proven track record of helping individuals overcome health barriers, including long-term conditions.

Vitality pioneered the category of incentivized healthy behavior change globally, and today leverages a massive dataset and AI, to provide highly personalized recommendations and rewards to encourage impactful and sustainable behavior change across its members globally. Vitality helps individuals to make healthier decisions during and outside care-seeking moments across the care continuum.

The WellSpark acquisition aligns with the business’s strategic direction of embedding more digital and innovative services within its offering, further benefitting clients and members.

WellSpark’s innovative coaching experience emphasizes human connection and leverages science and technology. It will improve outcomes and reduce healthcare costs for Vitality’s clients, employees and members. As part of the acquisition, Vitality will also partner with EmblemHealth to offer its members a full range of health and wellbeing solutions.

“Our acquisition of WellSpark is a fantastic opportunity to introduce an innovative coaching solution that meets our clients’ diverse needs,” said Maia Surmava, CEO of Vitality U.S. “WellSpark’s proven ability to make a clinical difference, even for hard-to-reach individuals, aligns perfectly with Vitality’s commitment to achieving better health for all our clients. We’re excited about how this acquisition opens up new opportunities to collaborate with EmblemHealth, offering their members our full range of health and wellbeing solutions. Our sophisticated digital tools complement WellSpark’s highly credentialed coaches, enabling us to deliver personalized, data-driven insights and support that empower individuals to achieve their health goals more effectively.”

Karen Ignagni, EmblemHealth CEO, said, “WellSpark has brought innovative coaching, personal support, and wellness engagement solutions to members in 30 states. We are proud to have launched WellSpark within our enterprise. The announcement today will see Vitality further grow the business and make a difference to many more people’s lives.”

Vitality was advised by Taft as its legal counsel and Houlihan Lokey as its financial advisor.

About Emblem Health

EmblemHealth is one of the nation’s largest nonprofit health insurers, with more than three million members and an 80+-year legacy of serving New York’s communities. The company offers a full range of commercial and government-sponsored health plans to employers, individuals, and families, as well as convenient community resources. As a market leader in value-based care, EmblemHealth partners with top providers and hospitals to deliver quality, affordable care. For more information, visit emblemhealth.com.

About Vitality

Guided by a core purpose of making people healthier, Vitality is the leader in improving health to unlock outcomes that matter. By blending industry-leading smart tech, data, AI, incentives, and behavioral science, we inspire healthy changes in individuals and organizations. As one of the largest health and wellbeing companies in the world, Vitality brings a dynamic and diverse perspective through successful partnerships with the most forward-thinking insurers and employers. More than 35 million people in 41 markets globally engage in the Vitality program. For more information, visit vitalitygroup.com.

Contacts

Cary Conway

cary@conwaycommunication.com (for media view only)